期刊文献+

孕激素治疗增生子宫内膜和高分化子宫内膜样癌后的临床病理形态观察 被引量:3

The observation of histological features after progestin treatment for endometrial hyperplasia and well-differentiated endometrioid carcinoma
下载PDF
导出
摘要 目的:显微镜下观察孕激素治疗对不同增生子宫内膜和高分化子宫内膜样腺癌的组织病理学影响,为临床更好地管理孕激素治疗提供依据。方法:收集2010年至2014年86例增生不伴有非典型增生(包括简单型增生、复杂型增生)和非典型增生及高分化子宫内膜样癌患者在我院经孕激素正规治疗刮宫至少两次以上病例,其中刮宫次数最多者达11次,时间2个月到5年。两个高年资病理医师双盲法显微镜下观察激素治疗前后病理改变。结果:简单型增生50名,基本转归为正常子宫内膜;复杂型增生18名,治疗约半年后转为正常子宫内膜;但其中2例有复发或恶化。非典型增生不伴/伴癌变18例,孕激素治疗后刮宫,10例镜下显示好转或完全缓解。好转病例显示组织结构依然复杂,但腺体间质比例降低,间质蜕膜样变或者玻璃样变;高倍镜下腺上皮细胞核变温和,核膜光滑,核仁不明显,核浆比例降低,胞浆丰富,伴嗜酸性变、鳞状细胞化生或粘液化生。该类病例继续治疗后,转化为正常周期宫内膜。但有4例(22.2%)在1-2年后复查,又出现非典型增生,甚至癌变。另有2个病例,治疗3个月后刮宫,镜下依然为非典型增生改变,证明孕激素治疗无效。结论:1)简单型增生过孕激素治疗效果好,3-6个月后刮宫,基本恢复正常周期。2)对非典型增生及癌变患者,因容易复发和恶化,按2014NCCN诊疗规范治疗坚持用药并定期复查非常有必要。3)非典型增生伴/不伴癌变病例,细胞学好转先于组织学。4)对治疗无效者,需要根据患者生育要求及时手术治疗。5)根据孕激素治疗效果评价,增生不伴非典型增生患者,区分简单型和复杂型增生依然有必要性。 Objective: To observe the pathological impact of progestin on endometrial hyperplasia and well-differentiated endometrioid carcinoma(WDC), and provide evidence for clinical administration to progestin treatment. Methods: A total of 86 cases of endometrial hyperplasia(including hyperplasia without atypia, atypical hyperplasia) and high differentiated endometrioid carcinomas with at least 2 curettage biopsies(most up to 11, from 2 months to 5 years) in our hospital and being given regular therapy were collected. Every slide was observed under microscope by two experienced pathologists. Results: There were 50 cases of simple hyperplasia and almost of them changed into normal endometrium. In 18 cases of complex hyperplasia, most of them were transformed into the normal, while 2 cases recurred or developed. In 18 cases of atypical hyperplasia and WDC, 10 got better or complete remission after about 3 months. These cases appeared decreased gland-to-stroma ratio with stroma decidual or hyaline changes. At higher power, cell changes were seen decreased nucleo-to-cytoplasmic ratio, mild gland cell nuclei, smoothened karyotheca, and eosinophilic, squamous or mucinous metaplasia. These cases eventually changed into normal endometrium after about several months to years' treatment. However, there were 4 cases(22.2%) arose to atypical hyperplasia even carcinoma again after 1-2 years. Another 2 atypical hyperplasia given progestin for 3 months had few changes which proofed the treatment was not effective. Conclusion: 1) The effect of progestin for simple hyperplasia was good; 2) for atypical hyperplasia and carcinoma, the standard and long-standing treatment according to NCCN guidance is necessary since these diseases are easily recurred or progressed; 3) during progestin treatment, for atypical hyperplasia and carcinoma, cellular changes are prior to that of architecture; 4) for those progestin non-effective cases, immediate operation is needed; 5) since progestin effect is different, for hyperplasia without atypical it is necessary to distinguish simple and complex hyperplasia.
出处 《临床与病理杂志》 2016年第4期450-455,共6页 Journal of Clinical and Pathological Research
基金 广东省科技厅基金(2013B021800307)~~
关键词 孕激素 子宫内膜增生过长 病理形态 progestin endometrium hyperplasia histological features
  • 相关文献

参考文献15

  • 1郭东辉,李灵敏,张慧娟,郑文新.子宫内膜样癌及癌前病变孕激素治疗后的病理评估及其临床意义[J].中华病理学杂志,2015,44(3):216-220. 被引量:10
  • 2Mylonas I, Jeschke U, Shabani N, et al. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrinm[J]. Histol Histopathol, 2007, 22(2): 169-176.
  • 3Mylonas I, Jeschke U, Shabani N, et al. Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium[J]. Acta Histochem, 2004, 106(3): 245-252.
  • 4Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger[J]. Obstet Gynecol, 1984, 64(3): 417-420.
  • 5Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate[J]. J Reprod Med, 1996, 41(5 Suppl): 428-433.
  • 6Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer[J]. Am J Obstet Gynecol, 2002, 186(4): 651-657.
  • 7Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer[J]. Obstet Gynecol, 2003, 102(4): 718-725.
  • 8Jobo T, Imai M, Kawaguchi M, et al. Successful conservative treatment of endometrial carcinoma permitting subsequent pregnancy: report of two cases [ J]. EurJ Gynaecol Oncol, 2000, 21 (2): 119-122.
  • 9Brown AJ, Westin SN, Broaddus RR, et al. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer[J]. Obstet Gynecol, 2012, 119(2 Pt 2): 423-426.
  • 10NCCN guidelines version 1. 2015 endometrial carcinoma[S], http:// www.nccn.org/.

二级参考文献22

  • 1Koh WJ,Greer BE,Abu-Rustum NR,et al. Uterine Neoplasms,version 1. 2014. [ J ]. J Natl Compr Cane Netw, 2014,12 (2 ):248-280.
  • 2Kurman RJ, Carcangiu ML, Herrington CS, et al. WHOclassicification of tumours of female reproductive organs [ M ].Lyon: IARC Press, 2014: 125-128.
  • 3Zheng W,Baker HE, Mutter GL. Involution of PTEN-nullendometrial glands with progestin therapy [ J ]. Gynecol Oncol,2004,92(3) :1008-1013.
  • 4Gunderson CC, Fader AN, Carson KA, et al. Oncologic andreproductive outcomes with progestin therapy in women withendometrial hyperplasia and grade 1 adenocarcinoma ; a systematicreview[ J]. Gynecol Oncol, 2012, 125(2) : 477-482.
  • 5Robboy SJ,Mutter GL, Prat J, et al. Robboy's pathology of femalereproductive tract[ M]. New York:Elsevier,2009:389.
  • 6Mazur MT, Kurman RJ. Diagnosis of endometrial biopsies andcurettings : a practical approach [ M ] . New York : Springer, 2005 :122-130.
  • 7Nucci MR, Crum CP. Altered endometrial differentiation(metaplasia) [ M/CD ]//Crum CP, Nucci MR, Lee KR, et al.Diagnostic gynecologic and obstetric pathology. New York :Saunders,2011:490.
  • 8Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations inendometrial hyperplasia and well-differentiated carcinoma treatedwith progestins[ J]. Am J Surg Pathol,2007 ,31(7) : 988-998.
  • 9Zaino RJ, Brady WE, Todd W,et al. Histologic effects ofmedroxyprogesterone acetate on endometrioid endometrialadenocarcinoma : a gynecologic oncology group study [ J ]. Int JGynecol Pathol, 2014, 33(6) :543-553.
  • 10Gunderson CC, Dutta S, Fader AN, et al. Pathologic featuresassociated with resolution of complex atypical hyperplasia andgrade 1 endometrial adenocarcinoma after progestin therapy [ J ].Gynecol Oncol, 2014,132( 1) : 33-37.

共引文献9

同被引文献26

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部